New Study Addresses FDA’s Concerns, Demonstrates CBD’s Safety Profile

The study observed the effects of daily consumption of CBD

A recent study released by Validcare directly addresses the U.S. Food and Drug Administration’s (FDA) safety concerns regarding CBD’s effects on the liver, testosterone levels and drowsiness.

The FDA’s safety concerns state that CBD in self-dosing individuals could cause liver injury, male reproductive toxicity, or damage males’ fertility, and increase the risk of sedation and drowsiness when mixed with alcohol or other drugs that slow brain activity.

The study, completed March 22, 2022, observed the effects of daily consumption of CBD on the liver, testosterone and daytime drowsiness. According to the abstract, the study included 1,061 adults ranging from 18-75 years old from across the U.S.

To Read The Rest Of This Article On Cannabis Business Times, Click Here

Stay up-to-date!

Get all the news and info straight into your inbox that you need to help grow your business.

Marijuana Retail Report, is a national daily online trade publication serving retailers of marijuana products and accessories. News and information are geared strictly to select retail channels, with distribution limited to licensed collectives, recreational retailers, accessories retailers, and wholesalers.


Stay informed with the most up-to-date industry news to help you grow your business: subscribe to our newsletter below!

To Top